News

According to data presented at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, composite efficacy data validate MCO-010 as a potential treatment for RP.

According to Clearside Biomedical, the suprachoroidal delivery of small molecule suspensions demonstrated targeted, compartmentalized and durable drug delivery.

Ophthalmology Times® talked with Bruce Ksander, PhD, about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells at this year's ARVO meeting.

Ophthalmology Times® talked with Steven Carrubba, MD, about monkeypox skin disease and eye disease in patients who were immunocompromised in New York at this year's ARVO meeting.

Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.

According to the company, consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating product profile.

The company shared data at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans that demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization lesions to a level comparable to D-4517.2 delivered subcutaneously and aflibercept administered intravitreally at the same mass dose in a laser-induced CNV mouse model.

In a presentation at ARVO 2023 in New Orleans, Yuyu Pharma’s YP-P10 is a novel, patented, synthetic peptide with anti-inflammatory properties being explored for the potential treatment of dry eye disease.

Physician discusses clinical presentations, treatment options for 2 cases.

Ophthalmology Times® talked with Christine Kay, MD, about the treatment of GUCY2D associated Leber congenital amaurosis type 1 at this year's ARVO meeting.

Ophthalmology Times® talked with Penny Asbell, MD, FACS, MBA, about the ARMOR study and antibiotic resistance at this year's ARVO meeting.

Ophthalmology Times® talked with Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.

Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration and diabetic macular edema.

Surgeon expects more MIGS, less trabeculectomy.

Conducting a thorough financial examination may help clinicians to see their finances as clearly as their patients see the world after cataract surgery.

Ophthalmology Times® talked with Roger Goldberg, MD, MBA, about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept at this year's ARVO meeting.

The company’s CT Lucia 621P monofocal IOL enables surgeons to treat a wide range of cataract patients while supporting optimized visual outcomes.

Instead, vitamins C and E may actually be associated with a slightly increased risk of DED.

Ophthalmology Times® talked with Edmund Arthur, OD, PhD, FAAO, about his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Body mass index (BMI), central obesity, and the metabolic syndrome may be deciding risk factors in glaucoma.

Ophthalmology Times® talked with Jay Barth, MD, about the work at Ascidian Therapeutics and their research into developing a new way to administer gene therapy at this year's ARVO meeting.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, it was noted ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment.

In a presentation at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, SB15 demonstrates comparable efficacy, safety, immunogenicity, and pharmacokinetics profiles to reference aflibercept up to Week 56.

Under a compassionate use program, the topical application of B-VEC to the eye was well tolerated and patient showed significant improvement of visual acuity and complete corneal re-epithelization. The company presented data at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans.

In a poster presented at the Association for Research in Vision and Ophthalmology, authors Paul S. Kayne, PhD, Alison Obr, PhD, John H. Dodd, PhD, and Carl Spana, PhD, it was demonstrated that PL9588 reduces ocular pressure. Data provides further support for topical administration of melanocortins for ocular inflammation.

Therapies to target geographic atrophy are in sight.

Francine Behar-Cohen, MD, PhD, presented the data at the Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.